Cutaneous amoebiasis is the dermatological manifestation of amoebic infection. Patients presenting with active clinical disease require prompt, evidence-based pharmacological management to achieve eradication of both tissue-invasive and intestinal stages of the parasite.

Treatment Approach

Clinical disease requires treatment with two distinct agents working in sequence: a tissue-active amebicidal agent to address invasive infection, followed by a luminal cysticidal agent to eliminate cysts. The selection of agents, their sequencing, and the timing of administration are precisely defined in the full protocol — only part of the approach is outlined here.

References

DOI: 10.1093/ofid/ofy161

Patients with clinical disease require treatment with 2 drugs: an amebicidal tissue-active agent and a luminal cysticidal agent.
The amebicidal agents include metronidazole and tinidazole, which are both nitroimidazole agents.
The nitroimidazoles do not effectively eradicate luminal cysts and must be followed by a luminal agent.
As it may cause diarrhea, paromomycin should not be administered at the same time as the nitroimidazole agent.
Diloxanide and iodoquinol are alternatives, but neither is available in the United States.

View source ↗

Treatment of Cutaneous Amoebiasis: A Sequential Two-Drug Approach

References